Traws Pharma, Inc. Retained Earnings
Traws Pharma, Inc. (TRAW) had Retained Earnings of -$650.14 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$650.14M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$647.09M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$639.98M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$632.54M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$650.14M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$647.09M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$639.98M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$632.54M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$628.58M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$627.66M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$649.15M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$619.23M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$610.76M 10-Q · filed 2024-08-15 |
| 2024-03-31 | -$487.61M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$482.63M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$478.45M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$473.71M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$469.46M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$463.68M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$458.26M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$452.87M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$448.84M 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$444.72M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$440.95M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$437.50M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$433.27M 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$428.56M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$422.13M 10-Q · filed 2020-11-16 |
| 2020-06-30 | -$415.89M 10-Q · filed 2020-08-12 |
| 2020-03-31 | -$408.49M 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$403.40M 10-K · filed 2021-03-18 |
| 2019-09-30 | -$397.65M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$393.06M 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$389.50M 10-Q · filed 2019-05-15 |
| 2018-12-31 | -$381.90M 10-K · filed 2020-03-27 |
| 2018-09-30 | -$376.25M 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$370.90M 10-Q · filed 2018-08-14 |
| 2018-03-31 | -$367.41M 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$362.32M 10-K · filed 2019-04-01 |
| 2017-09-30 | -$356.11M 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$349.15M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$346.56M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$338.22M 10-K · filed 2018-03-16 |
| 2016-09-30 | -$332.78M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$331.18M 10-Q · filed 2016-08-15 |
| 2016-03-31 | -$325.80M 10-Q · filed 2016-05-11 |
| 2015-12-31 | -$318.56M 10-K · filed 2017-03-29 |
| 2015-09-30 | -$321.75M 10-Q · filed 2015-11-12 |
| 2015-06-30 | -$315.88M 10-Q · filed 2015-08-13 |
| 2015-03-31 | -$306.92M 10-Q · filed 2015-05-15 |
| 2014-12-31 | -$294.58M 10-K · filed 2016-03-28 |
| 2014-09-30 | -$281.21M 10-Q · filed 2014-11-14 |
| 2014-06-30 | -$266.33M 10-Q · filed 2014-08-14 |
| 2014-03-31 | -$249.57M 10-Q · filed 2014-05-15 |
| 2013-12-31 | -$230.90M 10-K · filed 2015-03-30 |
| 2013-09-30 | -$216.28M 10-Q · filed 2013-11-14 |
| 2013-06-30 | -$195.76M 10-Q · filed 2013-09-06 |
| 2012-12-31 | -$168.35M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |